

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 September 2007 (13.09.2007)

PCT

(10) International Publication Number
WO 2007/103009 A3

(51) International Patent Classification:
A61K 45/00 (2006.01) A01N 63/00 (2006.01)
A61K 38/21 (2006.01)

(21) International Application Number:
PCT/US2007/004841

(22) International Filing Date:
23 February 2007 (23.02.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/778,516 1 March 2006 (01.03.2006) US

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CAI, Zeling [US/US]; 10516 Corte Jardin Del Mar, San Diego, CA 92130 (US). MORIARTY, Ann [US/US]; 13038 Lomas Verdes Drive, Poway, CA 92064 (US). PETERSON, Per, A. [SE/US]; 17475 Los Morros, Rancho Santa Fe, CA 92067 (US). RICHARDS, Jon, M. [US/US]; 3845 Timbers Edge Lane, Glenview, IL 60025 (US).

(74) Agent: EVANS, Linda, S.; Patent Law Department, Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, IP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
9 October 2008



WO 2007/103009 A3

(54) Title: CANCER TREATMENT COMBINING LYMPHODEPLETING AGENT WITH CTLs AND CYTOKINES

(57) Abstract: In a cancer treatment combining cell therapy with chemotherapy, autologous CD8⁺ T cells are obtained from a patient, activated ex vivo by contacting them with xenogenic antigen presenting cells loaded with selected peptide antigen, thereby generating antigen-specific activated cytotoxic T lymphocytes. Such activated CTLs are administered to the patient in conjunction with a lymphodepletion and CTL maintenance regimen comprising a non-myeloblastic but lymphdepleting agent, such as cladribine or denileukin diftitox, and interleukin-2 and interferon- α -2b stimulatory cytokines.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US07/04841

A. CLASSIFICATION OF SUBJECT MATTER

IPC: **A61K 45/00**(2006.0 1),**38/21**(**2006.01**);**A01N 63/00**(2006.01)

USPC: 424/85. 1,85.2,85.4,85.7,93.71

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/85.1,85.2,85.4,85.7,93.71

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Medline Biosis Lifesci Biotechds Scisearch Embase Hcaplus

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KOOPMANS et al. Porcine Fetal Ventral Mesencephalic Cells Are Targets for Primed Xenoreactive Human T Cells. Cell Transplantation. 2006, Vol. 15, pages 381-387.	1-7
A	SUN et al. The Interaction Defect of Accessory Molecules is Responsible for the Poor Ex Vivo Response to Human Antigens of Mouse T Helper Cells. Scandanavian Journal of Immunology. 2003, Vol. 58, pages 59-66.	1-7
A	PATEL et al. Class II MHC/Peptide Complexes Are Released from APC and Are Acquired by T Cell Responders During Specific Antigen REcognition. Journal of Immunology. 1999, Vol. 163, pages 5201-5210.	1-7
A	BARZAGA-GILBERT et al. Species Specificity and Augmentation of Responses to Class II Major Histocompatibility Complex Molecules in Human CD4 Transgenic Mice. Journal of Experimental Medicine. 1992, Vol. 175, pages 1707-1 715.	1-7

D Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X"	document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

24 May 2008 (24.05.2008)

Date of mailing of the international search report

25 JUL 2008

Name and mailing address of the ISA/US

Mail Stop PCT, Attn ISA/US
 Commissioner for Patents
 P O Box 1450
 Alexandria, Virginia 22313-1450

Facsimile No. (571) 273-3201

Authorized officer


 Karen A. Cahella

Telephone No. 571-272-1600